Please log in to determine if you are eligible to purchase PT Programs.
PLASMA CELL MYELOMA MRD - FL9
FL9
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

Procedure Challenges per Shipment Number of Shipments
Plasma cell myeloma minimal residual disease 3 Two shipments per year

Program FL9 is intended for laboratories that currently or will begin to perform minimal residual disease (MRD) testing (rare event analysis) for plasma cell myeloma.


Program Information

  • Two 4.5‑mL specimens containing a cell line/whole blood mixture simulating plasma cell myeloma minimal residual desease with clinical history and pertinent laboratory data
  • One online case with clinical history and gated dot plots

This program has stability of two days or less. The CAP cannot guarantee performance or offer credits for orders placed for shipment outside of the US and Canada.

Shipping Schedule

  • Shipment A: May 24
  • Shipment B: December 6